ASH 2022 | Siltuximab for first-line treatment of CRS in patients receiving CAR-T therapy
Paolo Caimi, MD, Cleveland Clinic, Cleveland, discusses outcomes following the substitution of tocilizumab with siltuximab to cope with the national tocilizumab shortage. Overall, it was observed that IL-6 blockade with siltuximab was an effective and feasible first-line therapy for cytokine release syndrome (CRS). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Bristol Myers Squibb: Membership on an entity’s Board of Directors or advisory committees; Genmab: Membership on an entity’s Board of Directors or advisory committees; Genentech: Membership on an entity’s Board of Directors or advisory committees; Takeda: Membership on an entity’s Board of Directors or advisory committees; MEI Pharma: Membership on an entity’s Board of Directors or advisory committees; ADC Therapeutics: Membership on an entity’s Board of Directors or advisory committees; Novartis: Membership on an entity’s Board of Directors or advisory committees; Kite Pharma: Membership on an entity’s Board of Directors or advisory committees.
